Oligonucleotide Therapeutics Society
OTS is a forum to foster academic and industry-based research and development of oligonucleotide therapeutics.
Nordic Digital Science & Innovation Day
Sharing the latest trends, innovations, and best practices for digitizing R&D assets to accelerate modern science.
Reducing R&D risk with explainable AI
Our explainable models yielded a 44 percentage point improvement in catching toxic drugs in the drug development pipeline
siRNA molecule activity: explainable AI models uncover underlying mechanisms
Our results-driven world pressures us to give up good science.
Abzu and Contera Pharma partner to design RNA therapeutics for rare diseases using xAI technology
Abzu, an applied research startup who has developed a pioneering explainable artificial intelligence (xAI), and Contera Pharma, a biotech company developing innovative therapies to treat neurological disorders, are partnering to design nucleic acid-based medicines. Abzu will collaborate exclusively with Contera Pharma on two undisclosed targets within rare neurological diseases.
AI and nucleic acid-based medicine: can symbolic regression unite them?
How the QLattice explains the cellular toxicity of RNA-targeting drugs.